Darin J. Weber - Aug 25, 2023 Form 4 Insider Report for PROKIDNEY CORP. (PROK)

Role
SVP of Regulatory Development
Signature
/s/ Todd Girolamo, as Attorney-in- Fact
Stock symbol
PROK
Transactions as of
Aug 25, 2023
Transactions value $
$0
Form type
4
Date filed
8/29/2023, 10:25 PM
Previous filing
Jan 18, 2023
Next filing
Feb 6, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PROK Class A Ordinary Shares Conversion of derivative security $0 +137K $0.00 137K Aug 25, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PROK Class B Ordinary Shares Conversion of derivative security $0 -137K -20.26% $0.00 539K Aug 25, 2023 Class A Ordinary Shares 137K $0.00 Direct F1, F2
transaction PROK Common Units in ProKidney LP Conversion of derivative security $0 -137K -20.26% $0.00 539K Aug 25, 2023 Class A Ordinary Shares 137K $0.00 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Class B Ordinary Shares and the Common Units in ProKidney LP (a "Common Unit") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for Class A Ordinary Shares on a one-for-one basis. On August 25, 2023, the reporting person provided ProKidney Corp. (the "Issuer") with notice of exchange, which exchange will be settled 60 days following the closing of the exchange period under the terms of the Exchange Agreement.
F2 The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire.
F3 The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire.